347 related articles for article (PubMed ID: 22361315)
1. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
[TBL] [Abstract][Full Text] [Related]
2. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification.
Shields CL; Kaliki S; Kim HJ; Al-Dahmash S; Shah SU; Lally SE; Shields JA
Cornea; 2013 Mar; 32(3):248-56. PubMed ID: 22580436
[TBL] [Abstract][Full Text] [Related]
3. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
4. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
Boehm MD; Huang AJ
Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
[TBL] [Abstract][Full Text] [Related]
6. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Sinha B; Kumar R
Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
8. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
Sturges A; Butt AL; Lai JE; Chodosh J
Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
[TBL] [Abstract][Full Text] [Related]
9. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
Galor A; Karp CL; Chhabra S; Barnes S; Alfonso EC
Br J Ophthalmol; 2010 May; 94(5):551-4. PubMed ID: 19493859
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Kumar S; Sinha BP; Imam N
Cornea; 2017 Mar; 36(3):327-331. PubMed ID: 28079688
[TBL] [Abstract][Full Text] [Related]
11. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review.
Karp CL; Galor A; Chhabra S; Barnes SD; Alfonso EC
Ophthalmology; 2010 Dec; 117(12):2241-6. PubMed ID: 20619462
[TBL] [Abstract][Full Text] [Related]
12. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
Chaugule SS; Park J; Finger PT
Indian J Ophthalmol; 2018 Jan; 66(1):55-60. PubMed ID: 29283124
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
Schechter BA; Koreishi AF; Karp CL; Feuer W
Ophthalmology; 2008 Aug; 115(8):1291-6, 1296.e1. PubMed ID: 18187195
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients.
Kaliki S; Singh S; Iram S; Tripuraneni D
Indian J Ophthalmol; 2016 Oct; 64(10):702-709. PubMed ID: 27905329
[TBL] [Abstract][Full Text] [Related]
16. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
Krilis M; Tsang H; Coroneo M
Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
[TBL] [Abstract][Full Text] [Related]
17. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
[TBL] [Abstract][Full Text] [Related]
18. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
Schechter BA; Schrier A; Nagler RS; Smith EF; Velasquez GE
Cornea; 2002 Jan; 21(1):6-11. PubMed ID: 11805499
[TBL] [Abstract][Full Text] [Related]
19. Surgical versus Medical Treatment of Ocular Surface Squamous Neoplasia: A Cost Comparison.
Moon CS; Nanji AA; Galor A; McCollister KE; Karp CL
Ophthalmology; 2016 Mar; 123(3):497-504. PubMed ID: 26686965
[TBL] [Abstract][Full Text] [Related]
20. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases.
Yousef YA; Finger PT
Ophthalmology; 2012 Feb; 119(2):233-40. PubMed ID: 22189448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
